HeyJaredBowTiedBiotech
Daily Biotech Public & Private Market Updates, Company Building, Financing, Exit Strategies, and Emerging Science Trends
- Indexed issues, last 90 days
- 22
- Latest publication
- Sep 28, 2026
- Audience
- Checking…
- Earliest in this view
- Sep 3, 2026
Latest issues
BIOTECH MARKET RESEARCH $PRAX | Ep. 1091 (opens the original)
Read excerpt
Praxis Precision Medicines ($PRAX) is a catalyst-driven setup centered on the December 27, 2026 FDA decision for relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies (DEEs). This is an FDA approval catalyst, not a clinical data readout. The decision matters because the NDA has been accepted for Priority Review following the EMBOLD study, which was stopped early at interim analysis after meeting its efficacy criteria. Relutrigine has also received Breakthrough Ther
The Desert Shortcut | Ep. 1090 (opens the original)
Read excerpt
Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week, we zoom in on a region that's quietly building one of the most compelling clinical development platforms in the world - Abu Dhabi. While most biotech roadmaps still default to the US or Australia for early trials, the UAE is assembling a fast, globally compliant, and investor-aligned alternative t
BowTiedBiotech Weekly: Breakthrough Approvals and the Durability of Innovation | Ep. 1089 (opens the original)
Read excerpt
Hello Avatar! Welcome to the BowtiedBiotech podcast, where science meets business! If you're fascinated by breakthrough biotech, bold innovations, and the business behind the science, you're in the right place. Each week, we dive into the world of biotech with fresh insights, sharp analysis, and the stories that are shaping the future of health. Whether you’re an industry insider, an investor, or just biotech-curious, we’ve got something for you.We are now publishing 7x per week according to the
Your Weekly Biotech News Fix | Ep. 1088 (opens the original)
Read excerpt
Hello Avatar! Another week of biotech news is in the history books. We are proud to bring you the latest edition of our weekly biotech news fix. The content is designed to be consumed as a quick scroll to bring readers up to speed on key events from the week. For those of you interested to read a bit more, we provide links to the source articles.We are now publishing 7x per week according to the following cadence:Mondays: StocksTuesdays: BiotechWednesdays: PodcastThursdays: Markets</
The Biotech Shell Game | Ep. 1087 (opens the original)
Read excerpt
Hello Avatar! Welcome to another week of biotech analysis. Today’s commentary, as always on Thursday, focuses on the general market update. This week confirmed the playbook. Biotech can rally and capital can return quickly, but funding is flowing to companies with clean catalysts and tight execution. Secondaries continue to dominate the financing landscape, while IPO activity remains scarce. Investors are rewarding near-term proof and punishing duration risk. In this environment, cost of capital
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.